<DOC>
	<DOCNO>NCT02501811</DOCNO>
	<brief_summary>This phase II , randomize , placebo-controlled clinical trial design assess feasibility , safety , effect autologous bone marrow-derived mesenchymal stem cell ( MSCs ) c-kit+ cardiac stem cell ( CSCs ) alone combination ( Combo ) , compare placebo ( cell-free Plasmalyte-A medium ) well , administer transendocardial injection subject ischemic cardiomyopathy .</brief_summary>
	<brief_title>Combination Mesenchymal C-kit+ Cardiac Stem Cells Regenerative Therapy Heart Failure</brief_title>
	<detailed_description>This randomize , placebo-controlled clinical trial design evaluate feasibility , safety , effect Combo , MSCs alone , CSCs alone compare placebo well subject heart failure ischemic etiology . Following successful lead-in phase , total one hundred forty-four ( 144 ) subject randomize ( 1:1:1:1 ) receive Combo , MSCs , CSCs , placebo . After randomization , baseline imaging , relevant harvest procedure , study product injection , subject follow 1 day , 1 week , 1 month , 3 month , 6 month 12 month post study product injection . All subject receive study product injection ( cell placebo ) use NOGA® XP Mapping Navigation System . Subjects delayed-enhanced magnetic resonance imaging ( DEMRI ) scan assess scar size LV function structure baseline 6 12 month post study product administration . All endpoint assess 6 12 month visit occur 180 ±30 day 365 ±30 day respectively day study product injection ( Day 0 ) . For purpose endpoint analysis safety evaluation , Investigators utilize `` intention-to-treat '' study population , however treat analysis also conduct .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Plasma-lyte 148</mesh_term>
	<criteria>1 . Be ≥ 21 &lt; 80 year age 2 . Have document coronary artery disease ( CAD ) evidence myocardial injury , LV dysfunction , clinical evidence HF 3 . Have `` detectable '' area myocardial injury define ≥ 5 % LV involvement ( infarct volume ) subendocardial involvement cMRI 4 . Have EF ≤ 40 % cMRI 5 . Be receive guideline‐driven medical therapy heart failure stable tolerated dos ≥ 1 month prior consent . For beta‐blockade `` stable '' define great 50 % reduction dose 100 % increase dose . 6 . Be candidate cardiac catheterization 7 . Have New York Heart Association ( NYHA ) class II III heart failure symptoms 8 . If female childbearing potential , willing use one form birth control duration study , undergo pregnancy test baseline within 36 hour prior injection 1 . Indication standardofcare surgery ( include valve surgery , placement leftventricular assist device , heart transplantation ) , coronary artery bypass grafting ( CABG ) procedure , and/or percutaneous coronary intervention ( PCI ) treatment ischemic and/or valvular heart disease . Subjects require undergo PCI undergo procedure minimum 3 month advance randomization . Subjects require undergo CABG undergo procedure minimum 4 month advance randomization . In addition , subject develop need revascularization follow enrollment undergo revascularization without delay . 2 . Valvular heart disease include 1 ) mechanical bioprosthetic heart valve ; 2 ) severe ( valve ) insufficiency/regurgitation within 12 month consent 3 . Aortic stenosis valve area ≤ 1.5 cm2 4 . History ischemic hemorrhagic stroke within 90 day consent 5 . History leave ventricular remodel surgical procedure utilize prosthetic material 6 . Presence pacemaker and/or implantable cardioverterdefibrillator ( ICD ) generator follow limitations/conditions : manufacture year 2000 lead implant &lt; 6 week prior consent nontransvenous epicardial , abandon lead subcutaneous ICDs leadless pacemaker condition , judgment devicetrained staff , would deem MRI contraindicate 7 . Pacemakerdependence ICD ( Note : pacemakerdependent candidate without ICD exclude ) 8 . A cardiac resynchronization therapy ( CRT ) device implant less 3 month prior consent 9 . Other MRI contraindication ( e.g . patient body habitus incompatible MRI ) 10 . An appropriate ICD fire antitachycardia pace ( ATP ) ventricular fibrillation ventricular tachycardia within 30 day consent 11 . Ventricular tachycardia ≥ 20 consecutive beat without ICD within 3 month consent , symptomatic Mobitz II high degree atrioventricular block without function pacemaker within 3 month consent 12 . Presence LV thrombus 13 . Evidence active myocarditis 14 . Baseline maximal oxygen consumption ( VO2 max ) great 75 % age gender base predictive value 15 . Baseline eGFR &lt; 35 ml/min/1.73m2 16 . Poorly control blood glucose level ( HbA1c &gt; 8.5 % ) and/or history proliferative retinopathy 17 . Hematologic abnormality evidence hematocrit &lt; 25 % , white blood cell &lt; 2,500/ul platelet count &lt; 100,000/ul 18 . Liver dysfunction evidence enzyme ( AST ALT ) ˃ 3 time upper limit normal ( ULN ) 19 . Coagulopathy ( INR ≥ 1.3 ) due reversible cause ( e.g. , warfarin and/or Factor Xa inhibitor ) . Subjects withdrawn anticoagulation exclude . 20 . HIV and/or active hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) 21 . Allergy radiographic contrast material adequately manage premedication 22 . Known allergy penicillin streptomycin 23 . History organ cell transplantation , except transplantation bone , skin , ligament , tendon , cornea 24 . History malignancy within 5 year ( i.e. , subject prior malignancy must disease free 5 year ) , exclude basal cell carcinoma clean border pathology report cervical carcinoma situ definitively treat 25 . Condition limit lifespan &lt; 1 year 26 . History drug abuse ( illegal `` street '' drug except marijuana , prescription medication use appropriately preexist medical condition ) alcohol abuse ( ≥ 5 drinks/day ˃ 3 month ) , document medical , occupational , legal problem arise use alcohol drug within past 24 month 27 . Chronic immunosuppressant therapy corticosteroid tumor necrosis factor alpha ( TNFα ) antagonists 28 . Participation investigational therapeutic device trial within 30 day consent 29 . Cognitive language barrier prohibit obtain inform consent study elements 30 . Pregnancy lactation plan become pregnant next 12 month 31 . Any condition , judgment Investigator Sponsor , would impair enrollment , study product administration , followup</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Heart Failure</keyword>
	<keyword>Ischemia</keyword>
	<keyword>Autologous Stem Cells</keyword>
	<keyword>LV dysfunction</keyword>
	<keyword>Mesenchymal Stem Cells</keyword>
	<keyword>ckit Cardiac Stem Cells</keyword>
	<keyword>Combination Cell Therapy</keyword>
	<keyword>LV function</keyword>
	<keyword>Functional status</keyword>
</DOC>